No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Pharmanutra S.p.A. functions as a pharmaceutical and nutraceutical enterprise, focusing on the research, development, design, and marketing of nutritional supplements and medical devices. Its market reach extends across Italy, other parts of Europe, the Middle East, the Far East, and globally. Moreover, the company manufactures and promotes pharmaceuticals, medical devices, over-the-counter (OTC) items, and nutraceuticals specifically for the pediatric population. Furthermore, Pharmanutra is a producer and supplier of raw materials and active ingredients to the food, pharmaceutical, and dietary supplement industries. Its diverse product portfolio features prominent brands like the SiderAL series (including SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med), the Cetilar range (Cetilar Crema, Cetilar Patch, Tape), along with ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. These products are distributed and sold through a network comprising sales representatives, wholesalers, pharmacies, and para-pharmacies. Established in 2003, the company's base of operations is in Pisa, Italy.
www.pharmanutra.itNo one on the platform currently holds PHN.MI.
No tracked institution reports a position in PHN.MI as of their last filing.
No one on the platform has traded PHN.MI yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 27.3% | 33.0% | 42.6% | — | — | — |
| Rev. Growth % | 13.4% | 17.6% | ||||
| Profit Margin % | 15.2% | 16.1% | 16.6% | |||
| Free Cash Flow Margin % | 12.5% | 7.5% | 10.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $156M | +17.9% | $2.59 | $2.57–$2.61 | — | 2 |
| 2027 | $182M | +16.6% | $3.27 | $3.25–$3.29 | — | 2 |
| 2028 | $208M | +14.4% | $3.83 | $3.75–$3.95 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 3 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-03-17 | $0.62 | $0.62 | +0.0% |
| 2025-03-14 | $0.54 | $0.36 | -33.1% |
| 2024-11-11 | $0.43 | $0.44 | +2.3% |
| $14M |
| — |
| PHIL.MIPhilogen S.p.A. | $23.25 | +0.00% | $671M | — |
| SFL.MISafilo Group S.p.A. | $1.71 | -0.12% | $674M | — |
Source: Financial Modeling Prep · peers by sector/industry